ALK EML4-ALK C1156Y–L1198F

在非小细胞肺癌（NSCLC）中，EML4-ALK C1156Y单独对环唑天宁具有抵抗力，这一现象已被额外的ALK突变所调节（同时增加敏感性和抵抗力）。一个病例报告显示，一个含有EML4-ALK C1156Y-L1198F的NSCLC对洛拉替尼有抵抗力，但第二个突变使该肿瘤对环唑替尼重新敏感。
EML4-ALK C1156Y alone is resistant to crizotinib in non-small cell lung cancer (NSCLC) which has been shown to be modulated (both increased sensitivity and resistance) by additional ALK mutations. A case report showed that an NSCLC harboring EML4-ALK C1156Y–L1198F was resistant to lorlatinib but this second mutation re-sensitized this tumor to crizotinib.